Protara Therapeutics, Inc. (TARA)
3.82
-0.17
(-4.26%)
USD |
NASDAQ |
Aug 28, 16:00
3.815
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Free Cash Flow : -66.49M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -66.49M |
| March 31, 2026 | -63.04M |
| December 31, 2025 | -56.46M |
| September 30, 2025 | -48.79M |
| June 30, 2025 | -44.78M |
| March 31, 2025 | -40.25M |
| December 31, 2024 | -35.87M |
| September 30, 2024 | -35.26M |
| June 30, 2024 | -33.42M |
| March 31, 2024 | -35.09M |
| December 31, 2023 | -37.60M |
| September 30, 2023 | -33.93M |
| June 30, 2023 | -32.77M |
| March 31, 2023 | -28.50M |
| December 31, 2022 | -26.58M |
| September 30, 2022 | -28.50M |
| June 30, 2022 | -29.20M |
| March 31, 2022 | -33.86M |
| December 31, 2021 | -35.10M |
| September 30, 2021 | -35.42M |
| June 30, 2021 | -33.18M |
| March 31, 2021 | -29.11M |
| December 31, 2020 | -24.29M |
| September 30, 2020 | -18.15M |
| Date | Value |
|---|---|
| June 30, 2020 | -15.79M |
| March 31, 2020 | -11.45M |
| December 31, 2019 | -5.486M |
| September 30, 2019 | -8.759M |
| June 30, 2019 | -10.34M |
| March 31, 2019 | -19.32M |
| December 31, 2018 | -23.35M |
| September 30, 2018 | -24.65M |
| June 30, 2018 | -27.47M |
| March 31, 2018 | -20.40M |
| December 31, 2017 | -22.39M |
| September 30, 2017 | -22.27M |
| June 30, 2017 | -23.04M |
| March 31, 2017 | -25.51M |
| December 31, 2016 | -23.96M |
| September 30, 2016 | -23.58M |
| June 30, 2016 | -20.92M |
| March 31, 2016 | -19.79M |
| December 31, 2015 | -17.76M |
| September 30, 2015 | -14.61M |
| June 30, 2015 | -14.28M |
| March 31, 2015 | -12.36M |
| December 31, 2014 | -10.04M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| NovelStem International Corp. | -0.2295M |
| Brainstorm Cell Therapeutics, Inc. | -4.057M |
| Summit Therapeutics, Inc. | -458.40M |
| Kezar Life Sciences, Inc. | -42.03M |
| Clene, Inc. | -16.00M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -15.39M |
| Cash from Investing (Quarterly) | 17.75M |
| Cash from Financing (Quarterly) | -0.026M |
| Free Cash Flow Per Share (Quarterly) | -0.2577 |
| Free Cash Flow to Equity (Quarterly) | -15.41M |
| Free Cash Flow to Firm (Quarterly) | -15.72M |
| Free Cash Flow Yield | -33.66% |